Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2005

Open Access 01-03-2005 | Research article

Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis

Authors: Loes Linsen, Marielle Thewissen, Kurt Baeten, Veerle Somers, Piet Geusens, Jef Raus, Piet Stinissen

Published in: Arthritis Research & Therapy | Issue 3/2005

Login to get access

Abstract

Natural killer T (NKT) cells have been implicated in the regulatory immune mechanisms that control autoimmunity. However, their precise role in the pathogenesis of rheumatoid arthritis (RA) remains unclear. The frequency, cytokine profile and heterogeneity of NKT cells were studied in peripheral blood mononuclear cells (PBMCs) from 23 RA patients and 22 healthy control individuals, including paired PBMC–synovial fluid samples from seven and paired PBMC–synovial tissue samples from four RA patients. Flow cytometry revealed a decreased frequency of NKT cells in PBMCs from RA patients. NKT cells were present in paired synovial fluid and synovial tissue samples. Based on the reactivity of PBMC-derived NKT cells toward α-galactosylceramide, RA patients could be divided into responders (53.8%) and nonresponders (46.2%). However, NKT cells isolated from synovial fluid from both responders and nonresponders expanded upon stimulation with α-galactosylceramide. Analysis of the cytokine profile of CD4+ and CD4- PBMC derived NKT cell lines from RA patients revealed a significantly reduced number of IL-4 producing cells. In contrast, synovial fluid derived NKT cell lines exhibited a Th0-like phenotype, which was comparable to that in healthy control individuals. This suggests that synovial fluid NKT cells are functional, even in patients with nonresponding NKT cells in their blood. We conclude that, because the number of Vα24+Vβ11+CD3+ NKT cells is decreased and the cytokine profile of blood-derived NKT cells is biased toward a Th1-like phenotype in RA patients, NKT cells might be functionally related to resistance or progression of RA. Providing a local boost to the regulatory potential of NKT cells might represent a useful candidate therapy for RA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG: NKT cells: facts, functions and fallacies. Immunol Today. 2000, 21: 573-583. 10.1016/S0167-5699(00)01735-7.CrossRefPubMed Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG: NKT cells: facts, functions and fallacies. Immunol Today. 2000, 21: 573-583. 10.1016/S0167-5699(00)01735-7.CrossRefPubMed
2.
go back to reference Lee PT, Benlagha K, Teyton L, Bendelac A: Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med. 2002, 195: 637-641. 10.1084/jem.20011908.PubMedCentralCrossRefPubMed Lee PT, Benlagha K, Teyton L, Bendelac A: Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med. 2002, 195: 637-641. 10.1084/jem.20011908.PubMedCentralCrossRefPubMed
3.
go back to reference Gumperz JE, Miyake S, Yamamura T, Brenner MB: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002, 195: 625-636. 10.1084/jem.20011786.PubMedCentralCrossRefPubMed Gumperz JE, Miyake S, Yamamura T, Brenner MB: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002, 195: 625-636. 10.1084/jem.20011786.PubMedCentralCrossRefPubMed
4.
go back to reference Wilson MT, Singh AK, Van Kaer L: Immunotherapy with ligands of natural killer T cells. Trends Mol Med. 2002, 8: 225-231. 10.1016/S1471-4914(02)02325-0.CrossRefPubMed Wilson MT, Singh AK, Van Kaer L: Immunotherapy with ligands of natural killer T cells. Trends Mol Med. 2002, 8: 225-231. 10.1016/S1471-4914(02)02325-0.CrossRefPubMed
5.
go back to reference Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M: CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998, 188: 1521-1528. 10.1084/jem.188.8.1521.PubMedCentralCrossRefPubMed Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M: CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998, 188: 1521-1528. 10.1084/jem.188.8.1521.PubMedCentralCrossRefPubMed
6.
go back to reference Nieda M, Nicol A, Koezuka Y, Kikuchi A, Takahashi T, Nakamura H, Furukawa H, Yabe T, Ishikawa Y, Tadokoro K, et al: Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol. 1999, 60: 10-19. 10.1016/S0198-8859(98)00100-1.CrossRefPubMed Nieda M, Nicol A, Koezuka Y, Kikuchi A, Takahashi T, Nakamura H, Furukawa H, Yabe T, Ishikawa Y, Tadokoro K, et al: Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum Immunol. 1999, 60: 10-19. 10.1016/S0198-8859(98)00100-1.CrossRefPubMed
7.
go back to reference Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L: Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol. 1999, 163: 2373-2377.PubMed Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L: Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol. 1999, 163: 2373-2377.PubMed
8.
go back to reference Burdin N, Brossay L, Kronenberg M: Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol. 1999, 29: 2014-2025. 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G.CrossRefPubMed Burdin N, Brossay L, Kronenberg M: Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol. 1999, 29: 2014-2025. 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G.CrossRefPubMed
9.
go back to reference Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, et al: Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998, 391: 177-181. 10.1038/34419.CrossRefPubMed Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, et al: Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998, 391: 177-181. 10.1038/34419.CrossRefPubMed
10.
go back to reference van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJ, et al: Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001, 100: 144-148. 10.1006/clim.2001.5060.CrossRefPubMed van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJ, et al: Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001, 100: 144-148. 10.1006/clim.2001.5060.CrossRefPubMed
11.
go back to reference Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T: Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001, 44: 1127-1138. 10.1002/1529-0131(200105)44:5<1127::AID-ANR194>3.0.CO;2-W.CrossRefPubMed Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T: Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001, 44: 1127-1138. 10.1002/1529-0131(200105)44:5<1127::AID-ANR194>3.0.CO;2-W.CrossRefPubMed
12.
go back to reference Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T: T(h)2 bias of CD4(+) NKT cells derived from multiple sclerosis in remission. Int Immunol. 2003, 15: 279-288. 10.1093/intimm/dxg029.CrossRefPubMed Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T: T(h)2 bias of CD4(+) NKT cells derived from multiple sclerosis in remission. Int Immunol. 2003, 15: 279-288. 10.1093/intimm/dxg029.CrossRefPubMed
13.
go back to reference Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001, 194: 1801-1811. 10.1084/jem.194.12.1801.PubMedCentralCrossRefPubMed Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001, 194: 1801-1811. 10.1084/jem.194.12.1801.PubMedCentralCrossRefPubMed
14.
go back to reference Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. 2001, 194: 1789-1799. 10.1084/jem.194.12.1789.PubMedCentralCrossRefPubMed Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. 2001, 194: 1789-1799. 10.1084/jem.194.12.1789.PubMedCentralCrossRefPubMed
15.
go back to reference Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona P, Casorati G, Martino G: Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol. 2003, 33: 1830-1838. 10.1002/eji.200323885.CrossRefPubMed Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona P, Casorati G, Martino G: Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol. 2003, 33: 1830-1838. 10.1002/eji.200323885.CrossRefPubMed
16.
go back to reference Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, et al: The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001, 7: 1052-1056. 10.1038/nm0901-1052.CrossRefPubMed Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, et al: The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001, 7: 1052-1056. 10.1038/nm0901-1052.CrossRefPubMed
17.
go back to reference Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, et al: Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001, 7: 1057-1062. 10.1038/nm0901-1057.CrossRefPubMed Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, et al: Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001, 7: 1057-1062. 10.1038/nm0901-1057.CrossRefPubMed
18.
go back to reference Okai M, Nieda M, Tazbirkova A, Horley D, Kikuchi A, Durrant S, Takahashi T, Boyd A, Abraham R, Yagita H, et al: Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang. 2002, 83: 250-253. 10.1046/j.1423-0410.2002.00217.x.CrossRefPubMed Okai M, Nieda M, Tazbirkova A, Horley D, Kikuchi A, Durrant S, Takahashi T, Boyd A, Abraham R, Yagita H, et al: Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang. 2002, 83: 250-253. 10.1046/j.1423-0410.2002.00217.x.CrossRefPubMed
19.
go back to reference VanderBorght A, Geusens P, Raus J, Stinissen P: The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum. 2001, 31: 160-175. 10.1053/sarh.2001.27736.CrossRefPubMed VanderBorght A, Geusens P, Raus J, Stinissen P: The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum. 2001, 31: 160-175. 10.1053/sarh.2001.27736.CrossRefPubMed
20.
21.
go back to reference Weyand CM, Goronzy JJ: T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol. 1999, 11: 210-217. 10.1097/00002281-199905000-00010.CrossRefPubMed Weyand CM, Goronzy JJ: T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol. 1999, 11: 210-217. 10.1097/00002281-199905000-00010.CrossRefPubMed
22.
go back to reference Kusaba M, Honda J, Fukuda T, Oizumi K: Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J Rheumatol. 1998, 25: 1466-1471.PubMed Kusaba M, Honda J, Fukuda T, Oizumi K: Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J Rheumatol. 1998, 25: 1466-1471.PubMed
23.
go back to reference Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S: Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 2004, 50: 305-313. 10.1002/art.11489.CrossRefPubMed Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S: Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 2004, 50: 305-313. 10.1002/art.11489.CrossRefPubMed
24.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed
25.
go back to reference van der AA, Hellings N, Bernard CC, Raus J, Stinissen P: Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. J Neuroimmunol. 2003, 137: 164-176. 10.1016/S0165-5728(03)00048-1.CrossRef van der AA, Hellings N, Bernard CC, Raus J, Stinissen P: Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. J Neuroimmunol. 2003, 137: 164-176. 10.1016/S0165-5728(03)00048-1.CrossRef
26.
go back to reference VanderBorght A, van der AA, Geusens P, Vandevyver C, Raus J, Stinissen P: Identification of overrepresented T cell receptor genes in blood and tissue biopsies by PCR-ELISA. J Immunol Methods. 1999, 223: 47-61. 10.1016/S0022-1759(98)00201-4.CrossRefPubMed VanderBorght A, van der AA, Geusens P, Vandevyver C, Raus J, Stinissen P: Identification of overrepresented T cell receptor genes in blood and tissue biopsies by PCR-ELISA. J Immunol Methods. 1999, 223: 47-61. 10.1016/S0022-1759(98)00201-4.CrossRefPubMed
27.
go back to reference Van Kaer L: Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol. 2004, 82: 315-322. 10.1111/j.0818-9641.2004.01252.x.CrossRefPubMed Van Kaer L: Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol. 2004, 82: 315-322. 10.1111/j.0818-9641.2004.01252.x.CrossRefPubMed
28.
go back to reference Hammond KJ, Godfrey DI: NKT cells: potential targets for autoimmune disease therapy?. Tissue Antigens. 2002, 59: 353-363. 10.1034/j.1399-0039.2002.590501.x.CrossRefPubMed Hammond KJ, Godfrey DI: NKT cells: potential targets for autoimmune disease therapy?. Tissue Antigens. 2002, 59: 353-363. 10.1034/j.1399-0039.2002.590501.x.CrossRefPubMed
29.
go back to reference Wilson MT, Van Kaer L: Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr Pharm Des. 2003, 9: 210-220. 10.2174/1381612033392080.CrossRef Wilson MT, Van Kaer L: Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr Pharm Des. 2003, 9: 210-220. 10.2174/1381612033392080.CrossRef
30.
go back to reference Maeda T, Keino H, Asahara H, Taniguchi M, Nishioka K, Sumida T: Decreased TCR AV24AJ18+ double-negative T cells in rheumatoid synovium. Rheumatology (Oxford). 1999, 38: 186-188.CrossRef Maeda T, Keino H, Asahara H, Taniguchi M, Nishioka K, Sumida T: Decreased TCR AV24AJ18+ double-negative T cells in rheumatoid synovium. Rheumatology (Oxford). 1999, 38: 186-188.CrossRef
31.
go back to reference Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T: Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol. 2000, 164: 4375-4381.CrossRefPubMed Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T: Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol. 2000, 164: 4375-4381.CrossRefPubMed
32.
go back to reference Matsuda JL, Gapin L, Fazilleau N, Warren K, Naidenko OV, Kronenberg M: Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor beta repertoire and small clone size. Proc Natl Acad Sci USA. 2001, 98: 12636-12641. 10.1073/pnas.221445298.PubMedCentralCrossRefPubMed Matsuda JL, Gapin L, Fazilleau N, Warren K, Naidenko OV, Kronenberg M: Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor beta repertoire and small clone size. Proc Natl Acad Sci USA. 2001, 98: 12636-12641. 10.1073/pnas.221445298.PubMedCentralCrossRefPubMed
33.
go back to reference Kojo S, Tsutsumi A, Goto D, Sumida T: Low expression levels of soluble CD1d gene in patients with rheumatoid arthritis. J Rheumatol. 2003, 30: 2524-2528.PubMed Kojo S, Tsutsumi A, Goto D, Sumida T: Low expression levels of soluble CD1d gene in patients with rheumatoid arthritis. J Rheumatol. 2003, 30: 2524-2528.PubMed
34.
go back to reference Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM: T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 2000, 97: 9203-9208. 10.1073/pnas.97.16.9203.PubMedCentralCrossRefPubMed Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM: T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 2000, 97: 9203-9208. 10.1073/pnas.97.16.9203.PubMedCentralCrossRefPubMed
35.
go back to reference Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, Joyce S, Wick MJ, Van Kaer L: The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA. 2003, 100: 10913-10918. 10.1073/pnas.1833166100.PubMedCentralCrossRefPubMed Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, Joyce S, Wick MJ, Van Kaer L: The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA. 2003, 100: 10913-10918. 10.1073/pnas.1833166100.PubMedCentralCrossRefPubMed
36.
go back to reference Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002, 3: 867-874. 10.1038/ni827.CrossRefPubMed Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002, 3: 867-874. 10.1038/ni827.CrossRefPubMed
37.
go back to reference Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, Strominger JL, Brenner MB, Gumperz JE, Wilson SB, et al: CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol. 2003, 171: 2571-2580.CrossRefPubMed Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, Strominger JL, Brenner MB, Gumperz JE, Wilson SB, et al: CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol. 2003, 171: 2571-2580.CrossRefPubMed
Metadata
Title
Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis
Authors
Loes Linsen
Marielle Thewissen
Kurt Baeten
Veerle Somers
Piet Geusens
Jef Raus
Piet Stinissen
Publication date
01-03-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1695

Other articles of this Issue 3/2005

Arthritis Research & Therapy 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.